Lumos Pharma Inc

Lumos Pharma — Q1 2022 Earnings Presentation

11 slides from Lumos Pharma's earnings presentation, May 10, 2022

  1. Slide 1: First Quarter 2022 Financial Results & Clinical Update

    1 First Quarter 2022 Financial Results & Clinical Update May 10, 2022

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform

  3. Slide 3: Agenda

    3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Officer • John McKew, PhD, President & Chief Scientific Officer

  4. Slide 4: Plan for Interim Analyses for OraGrowtH210 and OraGrowtH212 Trials

    4 Plan for Interim Analyses for OraGrowtH210 and OraGrowtH212 Trials ~ Enrollment in OraGrowtH210 Trial exceeds 50% ~ Interim Analysis for Phase 2 OraGrowtH210 Trial Interim Analysis for PK/PD OraGrowtH212 Trial • Interim analysis of data from 40 subjects at 6 months on therapy • 3 dose levels of or

  5. Slide 5: OraGrowtH210 Trial: Phase 2 Trial in PGHD

    5 OraGrowtH210 Trial: Phase 2 Trial in PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~40 trial sites US &

  6. Slide 6: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

    6 • n = up to 24 • Open-label study • PGHD patients • rhGH-treatment naïve • 12-month dosing • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endogenous GH pulsa

  7. Slide 7: Other Updates

    7 Other Updates FDA permits LUM-201 treatment beyond 12 months • After review of unblinded LUM-201 data from OraGrowtH Trials, FDA lifts partial clinical hold • OraGrowtH210 and OraGrowtH212 Trials extended beyond 12 months • Primary outcome data for OraGrowtH210 & OraGrowtH212 Trials at 6-months on

  8. Slide 8: MGH Initiated Phase 2 Pilot Trial in NAFLD

    8 • n = 10 • Adult NAFLD subjects with relative GH/IGF-1 deficiency • Open-label • Single-site pilot study • 6-month dosing Investigator Initiated Phase 2 Pilot Trial in Non-Alcoholic Fatty Liver Disease (NAFLD) Primary Objective: • Determine changes in intra- hepatic lipid content, inflammation, an

  9. Slide 9: Lumos Pharma Expands Leadership Team

    9 Lumos Pharma Expands Leadership Team Pisit Pitukcheewanont, MD – renowned pediatric endocrinologist • Vice President of Global Clinical Development and Medical Affairs for Lumos Pharma • Professor of Clinical Pediatrics at the Children’s Hospital of Los Angeles, Keck School of Medicine of the Univ

  10. Slide 10: Secure Cash Position

    10 Secure Cash Position Cash balance to support current operations through primary outcome data readouts for OraGrowtH210 and OraGrowtH212 Trials Metric Position Cash balance March 31, 2022 $86.8 million Cash use through 2022 $8.5 to $9.5 million per quarter Strong financial position Cash runway thr

  11. Slide 11: Investment Highlights

    11 Investment Highlights PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for gro

Lumos Pharma — Q1 2022 Earnings Presentation on 6ix